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INTRODUCTION
Recently, the focus of management in schizophrenia has
been shifting to early detection and intervention of the dis-
order. The primary prevention is to eliminate etiological risk
factors or to strengthen individual resistibility to the mor-
bid risk; however, these have not been shown to be effective
in schizophrenia to date. Instead, many researchers have been
interested in secondary early intervention, which is prevent-
ing or postponing the onset of psychosis, reducing the sever-
ity of illness, and enhancing treatment outcomes. 
During the past decade, clinical studies on first-episode
schizophrenia have revealed that the duration of untreated
psychosis (DUP) may be associated with short-term and/or
long-term outcomes, that is, a longer DUP is associated with
a poorer outcome of schizophrenia (1, 2). Also, according to
McGorry et al. (3), early therapeutic intervention during the
prodromal phase of schizophrenia may influence the overall
course of the disease. The onset of psychotic symptoms ob-
served in schizophrenia is frequently preceded by nonspecific
changes in behavior, emotional state, and/or cognitive state
(4), with common signs and symptoms of the prepsychotic
stage of schizophrenia including sleep disturbance, anxiety,
anger/irritability, depressed mood, deterioration in function-
ing, social withdrawal, poor concentration, suspiciousness,
loss of motivation, and low energy (5, 6). Therefore, it is crit-
ical that these signs and symptoms should be detected as early
as possible to reduce the duration of the prodromal phase.
There have been studies about the sex differences in the
manifestation of schizophrenia. According to Goldstein and
Lewine (7), males with schizophrenia generally have an earlier
onset of illness and a more severe form of the disease as reflect-
ed in greater cognitive or social impairment, while female
patients are more likely to suffer from anxiety and affective
symptoms (8). This sexual difference is regarded as a conse-
quence of different neuroendocrine and affective arousal sys-
tems (9). Thus, the early symptoms and signs experienced
and observed during the prodromal stage of schizophrenia
may differ between males and females with regard to their
frequency and relationship with other clinical characteristics.
However, relatively little work examined the gender differ-
ence of clinical manifestation in this population (10), although
several prospective studies examined gender as a predictive
variable of conversion to psychosis and found mixed results
(11, 12). Therefore, in the present study, we examined gen-
der differences in the prodromal symptoms experienced by
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Gender Difference in the Prodromal Symptoms of First-episode
Schizophrenia
To investigate the gender difference of early symptoms appearing before the onset
of the psychotic symptoms in patients with first-episode schizophrenia, we reviewed
the medical records of 63 patients (38 males, 25 females), who were hospitalized
for first-episode schizophrenia. The frequency and duration of prodromal and psy-
chotic symptoms, Clinical Global Impression scale scores, Global Assessment of
Functioning (GAF) scale scores at admission, and other clinical characteristics were
recorded for all patients. Overall, the most common prodromal symptoms were atten-
uated positive symptoms (89%), followed by mood symptoms (86%). Negative symp-
toms were the most common in male patients (97.4%), whereas attenuated positive
symptoms were the most common in female patients (84%). Male patients demon-
strated more frequent negative, cognitive, and obsessive-compulsive symptoms
than female patients did and also showed a tendency of having negative symptoms
for the longer period. Correlational analysis showed a significant negative correla-
tion between the duration of negative symptoms and GAF scores at admission in
male patients. Our findings suggest that different patterns of prodromal symptoms
between male and female begin before the onset of the psychosis. Further prospec-
tive studies should be needed. 
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the patients or observed by caregivers before the onset of first
psychotic symptoms in patients with first-episode schizophre-
nia. We hypothesized more affective symptoms in women
and more cognitive or negative symptoms in men would be
found during prodromal phase, as in patients with schizophre-
nia in previous studies.
MATERIALS AND METHODS
Subjects
This study was performed according to regulations on the
use of human subjects established by the institutional review
board of Seoul National University Hospital. We reviewed
the medical records of all patients admitted to the psychiatric
inpatient ward between March 2005 and February 2007 in
Seoul National University Hospital whose diagnoses at the
time of discharge were schizophrenia. 
Subjects included in the study met the following criteria.
First, the admission records were complete with detailed pre-
sent illness including all past psychiatric diagnoses, tentative
DSM-IV multi-axial diagnoses, Clinical Global Impression
(CGI) and Global Assessment of Functioning (GAF) scores.
Second, the discharge records were complete with definite
DSM-IV multi-axial diagnoses, CGI and GAF scores, and
signed by at least two psychiatrists. Third, the patients had
experienced either delusions or hallucinations for at least 1
month, regardless of the subtypes of schizophrenia they were
diagnosed with. Fourth, from previous medical records, it was
evident that patients had never been diagnosed with schizo-
phrenia before the admission. 
The authors discarded cases in which the section for pre-
sent illness lacked the evidence for the DSM-IV diagnosis of
schizophrenia, estimated onset of noticeable symptoms, or
CGI and GAF scores. The subjects either had never taken psy-
chotropic medication or had received pharmacotherapy for
less than 1 month. Patients who met the criteria for substance
use disorder, mental retardation, or major general medical
conditions associated with psychotic symptoms were also ex-
cluded from the study.
A total of 214 patients were admitted during the study
period and received a diagnosis of schizophrenia on discharge.
Among them, 63 patients (38 males, 25 females) met these
criteria. All had been admitted under the mental health act
with the permission of at least one eligible caregiver. The num-
bers of subjects diagnosed with each subtype of schizophre-
nia were as follows: paranoid (n=46), undifferentiated (n=12),
disorganized (n=4), and catatonic (n=1). Thirty-nine patients
(25 males, 14 females) had been treated with psychotropic
medication such as antipsychotics, antidepressants, and ben-
zodiazepines. The duration of pharmacotherapy did not exceed
1 month in any of them.
Assessments
The onsets of the prodromal phase and the psychotic phase
were estimated to the nearest 1 month according to the admis-
sion and discharge records by one of the authors. The onset
of the prodromal phase was defined as the appearance of the
first symptoms noticeable either to the patient him/herself
or to the caregiver(s) that were considered to indicate the ap-
pearance of the disease. The duration from the onset of pro-
dromal symptom to the onset of psychotic symptom was con-
sidered as the duration of prodromal symptom. The onset of
the psychotic phase was defined as the appearance of active
psychotic symptoms. In this study, prodromal symptoms were
categorized into 7 dimensions as follows: 1) attenuated pos-
itive symptoms (unusual thought content, suspiciousness,
unusual perceptual experiences, and disorganized speech),
2) negative symptoms (social withdrawal, decreased energy,
and flat affect), 3) cognitive changes (difficulties with concen-
tration and memory problems), 4) mood symptoms (depres-
sion, elation, and irritability), 5) anxiety, 6) obsessive com-
pulsive symptoms, and 7) somatic symptoms. These dimen-
sions were derived from the Instrument for the Retrospective
Assessment of Onset of Schizophrenia (13) and Criteria of
Prodromal Syndrome (14). The presence of symptoms from
each dimension was determined 1) if the symptom dimen-
sion was directly mentioned in the medical record either in
English or Korean, i.e, for dimension of mood symptoms,
phrases such as ‘‘mood disturbance’’, ‘‘depression (or depres-
sive mood)’’, ‘‘elation (or elated mood)’’, ‘‘irritability’’ or their
Korean equivalents or 2) if the authors could conclude the
presence of symptoms from each dimension from the descrip-
tion of the subjects’ thought, emotion and behavior from the
medical record.
Statistical analysis
Differences in the frequency of prodromal symptoms bet-
ween male and female patients were analyzed using a chi-
square test. Clinical characteristics or duration of overall and
individual prodromal symptoms were compared between male
and female patients using a t-test. Correlational analysis was
used to examine the relationships between the duration of
prodromal and/or psychotic symptoms and, CGI or GAF scale
score at admission in each gender. All analyses were two-tailed,
and significance was established at P<0.05.
RESULTS
The mean age of the study population was 24.66±5.62
yr. The duration of prodromal symptoms and psychotic symp-
toms were 5.63±4.53 yr and 0.82±1.07 yr, respectively.
On average, patients were admitted for 34.57±25.53 days.
At admission, mean CGI score and GAF scores were 5.71±Gender Difference in the Prodromal Symptoms of First-episode Schizophrenia 1085
0.58 and 35.08±12.33, respectively. 
A total of 17 males had axis I psychiatric diagnoses, includ-
ing obsessive-compulsive disorder (OCD), adjustment dis-
order, social phobia, and major depression, prior to the onset
of psychotic symptoms, whereas 12 females had prior axis I
diagnoses, including bipolar disorder, major depression, and
OCD before the onset of psychotic symptoms (Table 1). 
As shown in Table 2, no significant differences were detected
between genders in terms of age, age of onset, duration of
psychotic symptoms before admission, duration of admission,
as well as CGI and GAF scores. 
Fig. 1 shows the frequencies of the prodromal symptoms
in male and female patients. Overall, the most common symp-
toms were attenuated positive symptoms (89%) and mood
symptoms (86%). However, the most common symptoms
in males were negative symptoms (97.4%), whereas the most
common in females were attenuated positive symptoms (84%).
Significant differences were observed in the frequency of nega-
tive, cognitive, and obsessive-compulsive symptoms between
males and females. A total of 37 males (97.4%) and 14 females
(56%) experienced negative symptoms ( 2=14.16, P=0.000),
and 29 males (76.3%) and 10 females (40%) experienced cog-
nitive symptoms ( 2=6.96, P=0.008). Twenty males (52.6%)
and 5 females (20%) experienced obsessive-compulsive symp-
toms ( 2=4.55, P=0.033). No significant differences in other
symptoms were observed between two groups. Duration of
symptoms from each of the 7 dimensions did not significantly
differ between genders, although male patients suffered from
negative symptoms for a longer period than female patients
did (t=1.754, P=0.086). Further analyses showed that there
was a significant negative correlation between the duration
of negative symptoms (5.32±4.98 yr) and GAF score at ad-
mission in male patients (r=-0.341, P=0.039). This correla-
tion was not significant in female patients. 
DISCUSSION
Our findings demonstrated differences in the frequency of
prodromal symptoms between male and female patients with
first-episode schizophrenia. Negative symptoms and attenu-
ated positive symptoms were frequent in males, whereas atten-
uated positive symptoms and mood symptoms in females.
In addition, male patients showed more frequent prodromal
symptoms in negative, cognitive, and obsessive-compulsive
symptom dimensions than female patients did. 
In several studies, a prolonged DUP has been predictive
of poor prognosis (2, 15) and associated with sustained neu-
ropsychological deficits, increased negative symptoms and
disorganization, and unfavorable functional outcome of schi-
Table 1. Psychiatric diagnosis of patients with first-episode schi-
zophrenia during the prodromal phase
Diagnosis Male (n=38) Female (n=25)
Major depression 3 (7.9%) 3 (12.0%)
Bipolar disorder 1 (2.6%) 4 (16.0%)
Obsessive-compulsive disorder 4 (10.5%) 2 (8.0%)
Adjustment disorder 4 (10.5%) 0 (0%)
Social phobia 3 (7.9%) 0 (0%)
Brief psychotic disorder 2 (5.3%) 1 (4.0%)
Generalized anxiety disorder 0 (0%) 1 (4.0%)
Somatization 0 (0%) 1 (4.0%)
No diagnosis 21 (55.3%) 13 (52.0%)
Data are given as mean±SD.
DUP, duration of untreated psychosis; CGI, clinical global impression; GAF, global assessment of functioning.
Male (n=38) Parameters Female (n=25) t P value
Age (yr) 24.58±5.79 24.78±5.45 -0.134 0.894
Age at onset of prodromal symptoms (yr) 18.20±5.67 20.29±4.28 -1.569 0.122
Age at onset of first psychotic symptoms (yr) 23.81±5.86 23.87±5.52 -0.046 0.963
Estimated DUP (yr) 0.78±1.03 0.90±1.16 -0.455 0.651
Duration of admission (day) 31.53±23.84 39.61±27.91 -1.203 0.234
CGI score at admission 5.61±0.59 5.88±0.53 -1.876 0.065
GAF score at admission 36.32±8.36 32.20±13.08 -1.526 0.132
Table 2. Demographic and clinical characteristics of male and female patients with first-episode schizophrenia
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Fig. 1. Frequency of early symptoms during the prodromal phase
in patients with first-episode schizophrenia.
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zophrenia (16). Moreover, untreated psychosis may constitute
an active morbid process toxic to the brain. Lieberman et al.
(17) suggested that the process underlying toxic brain dam-
age may be halted by administering proper doses of olanza-
pine. So far, therefore, there have been many efforts to detect
patients presenting active psychotic symptoms and decrease
DUP. However, prior to the onset of psychotic symptoms,
many patients are usually suffering from various nonspecific
symptoms, such as depression, cognitive impairment, or neg-
ative symptoms. Additionally, duration of the prodromal
phase influenced grey and white matter volumes at the onset
of psychosis. That is, the severity of volumetric abnormalities
in first-episode psychosis was correlated with the duration
of the prodromal phase (18). In light of suffering, functional
decline and brain change of patients before the onset of active
psychotic symptoms, strategies for early detection and inter-
vention during the prodromal phase will likely gain further
prominence in the clinical setting.
According to a retrospective examination of early course
of patients with first-episode schizophrenia by Hafner et al.
(19), the 10 most frequent and earliest signs of schizophre-
nia such as restlessness, depression, anxiety, trouble with think-
ing and concentration, were reported by patients with a first-
episode illness. No gender differences were observed in the
earliest prodromal symptoms, except worrying, and the first
signs of a prodromal phase were depressive and negative symp-
toms. Whereas they reported the frequency of initial symp-
toms during the prodromal phase, we emphasized on the fre-
quency of all prodromal symptoms that patients had experi-
enced. Thus, negative, cognitive, and obsessive-compulsive
symptoms were more frequent in male patients than in female
patients. Cognitive change and negative symptoms such as
social withdrawal and decreased energy, may be associated
with impaired role functioning. In the present study, the GAF
score at admission was inversely correlated with the duration
of negative symptoms during the prodromal phase in male
patients, although there was no significant difference in the
GAF score between genders. Therefore, functional impair-
ment in males may be influenced by the duration of negative
symptoms even in the prodromal phase (R2=0.116). This
finding agrees with a report by Norman et al. (20) that showed
a correlation between impaired functioning in the prepsy-
chosis period and increased negative symptoms in schizophre-
nia spectrum disorders. 
Psychiatric syndromes such as mood disorders, cannabis
dependence (21), or anxiety disorders (22) are known to be
often comorbid with prodromal schizophrenia. Of 63 patients
included in this study, 29 (17 males, 12 females) had prior
psychiatric axis I diagnoses before the onset of active psychot-
ic symptoms. Interestingly, there were some differences in
the frequency of psychiatric diagnoses between the genders,
although a statistical power was not sufficient. Diagnoses
among male patients included OCD (n=4), adjustment dis-
order (n=4), and social phobia (n=3), whereas diagnoses among
female patients comprised bipolar disorder (n=4) and major
depression (n=3). Female patients tended to have a diagnosis
of mood disorder more often. On the contrary, male patients
had more frequent diagnoses associated with anxiety disor-
der. Considering that both male and female patients had most-
ly attenuated positive symptoms during the prodromal phase,
clinicians may need to pay attention to diagnose patients pre-
senting mood symptoms or anxiety symptoms combined
with attenuated positive symptoms. 
Previous studies have indicated that the DUP and dura-
tion of the prodromal phase differ between males and females.
Hafner et al. (23) reported that the prodromal period was
longer in females than in males, and the DUP has been shown
to be significantly longer in males than in females (24). Some
factors such as strength of social networks, degree of family
involvement, gender difference in help-seeking behavior, and
relative frequency of gender-specific stressors may lead to dif-
ferences in the DUP and the duration of the prodromal period
between genders (10, 25). Although no significant differences
were observed in the DUP and the duration of prodromal
symptoms between males and females in the present study,
the differences in the frequency of prodromal symptoms and
prior psychiatric diagnoses, and correlation of the duration
of negative symptoms with the GAF score at admission in
male may have been influenced by several factors. First, females
tend to express their emotions more readily and behave in a
relatively unobtrusive way. Thus, female patients may be more
likely to be misdiagnosed, for example, to be a mood disor-
der (26). Second, a relative younger age at onset of the pro-
dromal phase in males may also adversely affect their social
and cognitive development, resulting in more frequent neg-
ative and cognitive symptoms and a negative correlation bet-
ween the duration of negative symptoms and the GAF score
at admission in male patients. Additionally, these phenome-
nological differences may be derived from neurobiological
differences between males and females. Estrogen protects neu-
ral circuits by reducing the sensitivity of D2 receptors in the
central nervous system and by acting as a neuromodulator
with agonistic effects on other transmitter systems, such as
serotonin and glutamate (19, 27). Pohjalainen et al. (28) con-
ducted a positron emission tomography study to evaluate the
striatal dopamine D2 receptor binding characteristics in 33
healthy males and in 21 healthy females and found that the
female group had lower dopamine D2 receptor affinity than
the male group. In addition, the prolactin response to neu-
roleptic medications was greater in females than in males.
Kinon et al. (29) reported that among patients receiving treat-
ment with risperidone, females were 2.6 times more likely
to develop hyperprolactinemia than males. Moreover, sub-
jective tolerability of antipsychotics differed between genders.
Extrapyramidal and anticholinergic reactions were more fre-
quent among female patients, whereas sexual problems were
more frequent among male patients (30). In terms of these
neurobiological and symptomatological differences, malesGender Difference in the Prodromal Symptoms of First-episode Schizophrenia 1087
and females could not be regarded as homogenous group, and
therefore, clinicians and researchers should consider the role
of gender in the evaluation and treatment of patients.
The present study had several limitations. First, our retro-
spective chart review is prone to recall and report bias. The
onset of prodromal and active psychotic symptoms was deter-
mined according to the information provided by patients and
their family members. The extent of exploration in the his-
tory taking between doctors may have varied. However, we
excluded cases whose sources were lacking and chose only cases
with comprehensive information. Furthermore, as all of our
subjects were admitted for the first time, they may be less
prone to recall bias compared to recurrent or chronic patients,
although diagnostic stability of these patients may be some-
what compromised. Second, as all subjects in our study were
hospitalized, presumably having more severe symptoms, they
might represent the patient population with more severe
symptoms. Third, data in this study were descriptive and
none pertained to the severity of prodromal and psychotic
symptoms, except the GAF and CGI scores at admission. The
purpose of this study was to investigate the differences in the
frequency of early symptoms and signs during the prodromal
phase between male and female patients. Therefore, we did
not have systematic data to evaluate the severity of symptoms. 
In conclusion, our present findings provide evidence for
gender differences in the pattern of prodromal symptoms in
patients with first-episode schizophrenia. Although our study
was retrospective and explorative in its nature, our result alone
points that gender differences in prodromal symptoms should
be considered when assessing patients presenting nonspecif-
ic symptoms combined with attenuated positive symptoms.
Further prospective studies exploring the relationship bet-
ween gender differences in prodromal symptoms and long-
term outcomes are warranted.
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